DARE-HPV not checked

Daré Bioscience, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A fixed-dose ration combination (12:1) of lopinavir and ritonavir in a vaginal capsule.”In the company’s words, NCT07601074 on ClinicalTrials.gov
Tested for
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Main trialPhase 2
“The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.”In the company’s words, NCT07601074 on ClinicalTrials.gov
Other names
Lopinavir / ritonavir

Other drugs for Human Papilloma Virus (HPV)

All 7 drugs for Human Papilloma Virus (HPV)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Oct 2027 A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow DARE-HPV

Following is part of Solo: you see every change to DARE-HPV the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in